会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Modified T cell receptors and related materials and methods
    • 改良T细胞受体及相关材料及方法
    • US09128080B2
    • 2015-09-08
    • US13304841
    • 2011-11-28
    • Paul F. RobbinsRichard A. MorganSteven A. Rosenberg
    • Paul F. RobbinsRichard A. MorganSteven A. Rosenberg
    • C07H21/04G01N33/50C07K14/725A61K38/00
    • G01N33/505A61K38/00C07K14/7051G01N33/5091
    • The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
    • 本发明涉及包含不超过三个氨基酸取代的野生型(WT)TCR的氨基酸序列的修饰的T细胞受体(TCR),其中与WT TCR相比,修饰的TCR(i )当由CD4 + T细胞表达时具有增强的识别靶细胞的能力,和(ii)当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽,蛋白质,核酸,重组表达载体,宿主细胞,细胞群,抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外,本发明涉及检测宿主中的病变细胞的方法,治疗或预防宿主疾病的方法,以及鉴定候选的过继性免疫治疗TCR的方法。